We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alzamend Neuro, Inc. (ALZN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Alzamend Neuro, Inc. is one of 1010 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alzamend Neuro, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALZN's full-year earnings has moved 88.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALZN has returned 1.7% so far this year. Meanwhile, the Medical sector has returned an average of -3.3% on a year-to-date basis. As we can see, Alzamend Neuro, Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Beam Therapeutics Inc. (BEAM - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6.4%.
Over the past three months, Beam Therapeutics Inc.'s consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Alzamend Neuro, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has lost an average of 11.9% so far this year, meaning that ALZN is performing better in terms of year-to-date returns. Beam Therapeutics Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Alzamend Neuro, Inc. and Beam Therapeutics Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Alzamend Neuro, Inc. (ALZN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Alzamend Neuro, Inc. is one of 1010 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Alzamend Neuro, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALZN's full-year earnings has moved 88.2% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALZN has returned 1.7% so far this year. Meanwhile, the Medical sector has returned an average of -3.3% on a year-to-date basis. As we can see, Alzamend Neuro, Inc. is performing better than its sector in the calendar year.
Another stock in the Medical sector, Beam Therapeutics Inc. (BEAM - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6.4%.
Over the past three months, Beam Therapeutics Inc.'s consensus EPS estimate for the current year has increased 2.5%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Alzamend Neuro, Inc. is a member of the Medical - Biomedical and Genetics industry, which includes 512 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has lost an average of 11.9% so far this year, meaning that ALZN is performing better in terms of year-to-date returns. Beam Therapeutics Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Alzamend Neuro, Inc. and Beam Therapeutics Inc. as they attempt to continue their solid performance.